Oncovista Innovative Therapies Inc. Stock Analysis OVIT

OncoVista Innovative Therapies, Inc. is a drug development company, which engages in the development and commercialization of targeted cancer therapies. The company is headquartered in San Antonio, Texas. The company went IPO on 2006-01-23. The firm is engaged in developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The firm's product pipeline consists of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The firm's therapeutic strategy is based on targeting the patient's tumors with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The firm's products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity.